© 1994 by Oxford University Press
Journal of the National Cancer Institute, Vol. 86, No. 8, 600-607,
April 20, 1994
© 1994 Oxford University Press
Validation of the Gail et al. Model for Predicting Individual Breast Cancer Risk
*Department of Epidemiology and Department of Biostatistics, Harvard School of Public Health Boston, Mass
Department of Epidemiology, Harvard School of Public Health Boston, Mass
The Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Department of Epidemiology, Harvard School of Public Health Boston
Donna Spiegelman, Sc D., Department of Epidemiology, Harvard School of Public Health, 677 Huntington Ave., Boston, MA 02115.
Background: The Gail et al. model is considered the best available means for estimating an individual woman's risk of developing breast cancer. Such estimates are useful in decision making on the part of women, in designing prevention trials, and in targeting screening and prevention efforts. Purpose: Our purpose was to evaluate the ability of the model to accurately predict individual breast cancer risk, using a large population independent of the one from which the model was derived. Methods: We compared the number of cancer cases predicted by the model to the actual number of cases observed in the Nurses' Health Study. The study population was 115 172 women who did not have breast cancer at the beginning of the study. Questionnaires were sent to participants every 2 years, seeking data on risk factors and diagnoses of breast cancer. Follow-up compliance was 95% over the 12-year study period. Results: The model overpredicted absolute breast cancer risk by 33% (95% confidence interval [CI] = 28%–39%), with the overprediction more than twofold among premenopausal women (95% CI = 1.9–2.2), among women with extensive family history of breast cancer (95% CI = 1.1–3.9), and among women with age at first birth younger than 20 years (95% CI = 1.3–4.7). The correlation coefficient between observed and predicted risk was 0.67, indicating that the model is less than satisfactory for ranking individual levels of breast cancer risk. Overprediction occurred at all deciles of predicted risk. Conclusions: The model's performance is unsatisfactory for estimating breast cancer risk for individual women aged 25–61 years who do not participate in annual screening. Lower mammography screening rates in the Nurses' Health Study may account for some, but not all, of the discrepancy between observed and predicted cases. Implications: A recent modification of the model by the tamoxifen trial investigators is likely to have provided accurate power calculations. This modified form of the model should be useful for planning other large, population-based studies. [J Natl Cancer Inst 86: 600–607, 1994]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction J. Clin. Oncol., July 1, 2009; 27(19): 3235 - 3258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Cummings, J. A. Tice, S. Bauer, W. S. Browner, J. Cuzick, E. Ziv, V. Vogel, J. Shepherd, C. Vachon, R. Smith-Bindman, et al. Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk J Natl Cancer Inst, March 18, 2009; 101(6): 384 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Pankratz, L. C. Hartmann, A. C. Degnim, R. A. Vierkant, K. Ghosh, C. M. Vachon, M. H. Frost, S. D. Maloney, C. Reynolds, and J. C. Boughey Assessment of the Accuracy of the Gail Model in Women With Atypical Hyperplasia J. Clin. Oncol., November 20, 2008; 26(33): 5374 - 5379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, G. L. Anderson, D. S. Lane, A. K. Aragaki, T. Rohan, S. Yasmeen, G. Sarto, C. A. Rosenberg, F. A. Hubbell, and For the Women's Health Initiative Investigators Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status J Natl Cancer Inst, November 21, 2007; 99(22): 1695 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lithgow, A. Nyamathi, D. Elashoff, O. Martinez-Maza, and C. Covington C-reactive Protein in Nipple Aspirate Fluid Associated With Gail Model Factors Biol Res Nurs, October 1, 2007; 9(2): 108 - 116. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. M. Coyle, X.-J. Xie, C. M. Lewis, D. Bu, S. Milchgrub, and D. M. Euhus Role of Physical Activity in Modulating Breast Cancer Risk as Defined by APC and RASSF1A Promoter Hypermethylation in Nonmalignant Breast Tissue Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 192 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Elmore and S. W. Fletcher The Risk of Cancer Risk Prediction: "What Is My Risk of Getting Breast Cancer?" J Natl Cancer Inst, December 6, 2006; 98(23): 1673 - 1675. [Full Text] [PDF]
|
|
|
|
|
|
A. Decarli, S. Calza, G. Masala, C. Specchia, D. Palli, and M. H. Gail Gail Model for Prediction of Absolute Risk of Invasive Breast Cancer: Independent Evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition Cohort J Natl Cancer Inst, December 6, 2006; 98(23): 1686 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Bondy and L. A. Newman Assessing breast cancer risk: evolution of the gail model. J Natl Cancer Inst, September 6, 2006; 98(17): 1172 - 1173. [Full Text] [PDF]
|
|
|
|
|
|
W. E. Barlow, E. White, R. Ballard-Barbash, P. M. Vacek, L. Titus-Ernstoff, P. A. Carney, J. A. Tice, D. S. M. Buist, B. M. Geller, R. Rosenberg, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst, September 6, 2006; 98(17): 1204 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kendall and M. Dowsett Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr. Relat. Cancer, September 1, 2006; 13(3): 827 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Taylor and K. Taguchi Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump Ann. Fam. Med, May 1, 2005; 3(3): 242 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Tice, R. Miike, K. Adduci, N. L. Petrakis, E. King, and M. R. Wrensch Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 324 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Lewis, L. R. Cler, D.-W. Bu, S. Zochbauer-Muller, S. Milchgrub, E. Z. Naftalis, A. M. Leitch, J. D. Minna, and D. M. Euhus Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk Clin. Cancer Res., January 1, 2005; 11(1): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Newman Breast Cancer in African-American Women Oncologist, January 1, 2005; 10(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Arun Ductal Lavage and Risk Assessment of Breast Cancer Oncologist, November 1, 2004; 9(6): 599 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pichert, B. Bolliger, K. Buser, and O. Pagani Evidence-based management options for women at increased breast/ovarian cancer risk Ann. Onc., January 1, 2003; 14(1): 9 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Kinsinger, R. Harris, S. H. Woolf, H. C. Sox, and K. N. Lohr Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 2, 2002; 137(1): 59 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. McTiernan, A. Kuniyuki, Y. Yasui, D. Bowen, W. Burke, J. B. Culver, R. Anderson, and S. Durfy Comparisons of Two Breast Cancer Risk Estimates in Women with a Family History of Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 333 - 338. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Gail and J. P. Costantino Validating and Improving Models for Projecting the Absolute Risk of Breast Cancer J Natl Cancer Inst, March 7, 2001; 93(5): 334 - 335. [Full Text] [PDF]
|
|
|
|
|
|
B. Rockhill, D. Spiegelman, C. Byrne, D. J. Hunter, and G. A. Colditz Validation of the Gail et al. Model of Breast Cancer Risk Prediction and Implications for Chemoprevention J Natl Cancer Inst, March 7, 2001; 93(5): 358 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B Claus Risk models in genetic epidemiology Statistical Methods in Medical Research, December 1, 2000; 9(6): 589 - 601. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J. Smedira Practical Issues in Counseling Healthy Women About Their Breast Cancer Risk and Use of Tamoxifen Citrate Arch Intern Med, November 13, 2000; 160(20): 3034 - 3042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian, B. F. Kimler, C. M. Zalles, J. R. Klemp, S. Kamel, S. Zeiger, and M. S. Mayo Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model J Natl Cancer Inst, August 2, 2000; 92(15): 1217 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Eccles, D G R Evans, and J Mackay Guidelines for a genetic risk based approach to advising women with a family history of breast cancer J. Med. Genet., March 1, 2000; 37(3): 203 - 209. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Armstrong, A. Eisen, and B. Weber Assessing the Risk of Breast Cancer N. Engl. J. Med., February 24, 2000; 342(8): 564 - 571. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Garber A 40-Year-Old Woman With a Strong Family History of Breast Cancer JAMA, November 24, 1999; 282(20): 1953 - 1960. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gail, J. P. Costantino, J. Bryant, R. Croyle, L. Freedman, K. Helzlsouer, and V. Vogel Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1829 - 1846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Costantino, M. H. Gail, D. Pee, S. Anderson, C. K. Redmond, J. Benichou, and H. S. Wieand Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence J Natl Cancer Inst, September 15, 1999; 91(18): 1541 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan and M. Morrow Tamoxifen, Raloxifene, and the Prevention of Breast Cancer Endocr. Rev., June 1, 1999; 20(3): 253 - 278. [Abstract] [Full Text]
|
|
|
|
|
|
T. Brunoski, L. H. Powell, J. A. Blackman, T. L. Bush, K.S. Joseph, W. D. Dupont, D.R. Wigg, A. Z. Bluming, G. A. Colditz, W. C. Willett, et al. Breast Cancer and Hormone-Replacement Therapy N. Engl. J. Med., November 16, 1995; 333(20): 1355 - 1358. [Full Text]
|
|